Epidemiology, diagnosis and treatment ofClostridium difficileinfection
- 1 December 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anti-infective Therapy
- Vol. 10 (12), 1405-1423
- https://doi.org/10.1586/eri.12.135
Abstract
Clostridium difficile infection (CDI) is considered to be the main cause of bacterial infectious diarrhea in nosocomial settings. Since the beginning of the new century a continuous rise in the incidence of severe CDI has been observed worldwide. Even though some CDI cases are not associated with previous antibiotic exposure, this remains as the principal risk factor for the development of CDI. The rate of recurrences represents perhaps one the most challenging aspect on the management of CDI. There are several microbiological tests available, but glutamate dehydrogenase antigen test can be selected as the first screening step in a diagnostic algorithm, with positive samples then confirmed using a toxin(s) test, to distinguish toxinogenic from nontoxinogenic CDI. Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical and therapeutical needs. Usually oral metronidazole is recommended for initial treatment of nonsevere CDI and vancomycin for treatment of severe disease. Fidaxomicin may be considered in patients who cannot tolerate vancomycin, although more data are needed. For treatment of a nonsevere initial recurrence of CDI, oral metronidazole should be used, but for treatment of subsequent recurrences or more severe cases fidaxomicin may be helpfulKeywords
This publication has 99 references indexed in Scilit:
- Changing Epidemiology of Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based Surveillance Scheme in EnglandClinical Infectious Diseases, 2012
- Diagnostic Accuracy of Real-time Polymerase Chain Reaction in Detection of Clostridium difficile in the Stool Samples of Patients With Suspected Clostridium difficile Infection: A Meta-AnalysisClinical Infectious Diseases, 2011
- A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infectionJournal of Antimicrobial Chemotherapy, 2011
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratoryJournal of Medical Microbiology, 2011
- A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease SeverityClinical Infectious Diseases, 2007
- Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and RifaximinClinical Infectious Diseases, 2007
- Epidemics of Diarrhea Caused by a Clindamycin-Resistant Strain ofClostridium difficilein Four HospitalsThe New England Journal of Medicine, 1999
- Rapid polymerase chain reaction method for specific detection of toxigenicClostridium difficileEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Nosocomial Acquisition ofClostridium difficileInfectionThe New England Journal of Medicine, 1989